Insider Sale: Director at $VNDA Sells 7,000 Shares

Director Stephen Ray Mitchell sold 7,000 shares of $VNDA on 06-13-2025 for approximately $32,130, representing 6.7% of their holdings; over the past six months, insiders have predominantly purchased shares, with CEO Mihael Hristos Polymeropoulos buying 90,000 shares. Institutional investors show mixed sentiment, with Nantahala Capital Management liquidating its entire position of 1,593,516 shares in Q4 2024, while Millennium Management LLC added 1,470,898 shares in Q1 2025.

Analysis

Vanda Pharmaceuticals ($VNDA) exhibits contrasting signals from recent insider and institutional trading activity. A director, Stephen Ray Mitchell, sold 7,000 shares (6.7% of his holdings) for an estimated $32,130 on June 13, 2025, leaving him with 97,082 shares. This sale, however, stands against a backdrop of predominantly bullish insider activity over the past six months, with 13 purchases versus only this one sale among 14 transactions. Notably, President and CEO Mihael Hristos Polymeropoulos has been a significant buyer, acquiring 90,000 shares for approximately $416,307, while SVP, CFO & Treasurer Kevin Patrick Moran also purchased 2,000 shares. Institutional sentiment is similarly divergent. While Nantahala Capital Management LLC liquidated its entire position of 1,593,516 shares in Q4 2024, Q1 2025 saw substantial new inflows, exemplified by Millennium Management LLC adding 1,470,898 shares (+220.0%) and Krensavage Asset Management, LLC increasing its holding by 654,049 shares (+651.9%). Conversely, other institutions like Morgan Stanley and Schroder Investment Management Group reduced their positions by 423,783 shares (-31.6%) and 371,559 shares (-35.8%) respectively in Q1 2025. Overall, data from the most recent quarter indicates 64 institutional investors adding shares against 93 decreasing their positions, reflecting a mixed conviction on the stock's prospects.

Key Decisions for Investors

• Investors should weigh the significant CEO-led insider buying as a strong positive signal, despite a recent, smaller director sale.
• The divergent institutional activity, particularly the large Q4 2024 exit by Nantahala versus substantial Q1 2025 entries by Millennium and Krensavage, warrants cautious interpretation and close monitoring of subsequent quarterly filings for trend confirmation.
• Consider the overall mixed sentiment signals, implying that further due diligence on VNDA's specific catalysts or risk factors is crucial before making significant investment adjustments.